Clinical Trial Update: Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury [Phase 2]

View source ↗

Summary

Phase 2 trial of cobiprostone for prevention of NSAID-induced gastroduodenal injury completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nsaid-induced Gastroduodenal Injury
• Osteoarthritis
• Rheumatoid Arthritis
• Ulcers

Drugs mentioned

• cobiprostone (cobiprostone)

Snippet

Sponsor: Sucampo Pharma Americas, LLC | Conditions: NSAID-induced Gastroduodenal Injury, Ulcers | Phase 2 | Status: COMPLETED | Results posted: 2019-12-26